Aberrant miR-215 expression is associated with clinical outcome in breast cancer patients

Zhou, Shuwei; Su, Beibei; Zhou, Yong; Feng, Yechen; Guo, Yu; Wang, Yunxiang; Pan, Qi; Xu, Sheng

doi:10.1007/s12032-014-0259-2

Cited by 30 publications

(33 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The expression level of miR-215 was demonstrated to be associated with the International Federation of Gynecology and Obstetrics stage, the histological grade, and the extents of vascular invasion and lymph node metastasis of cervical cancer; the 5-year survival rate was lower in patients with stage II cervical cancer who exhibited miR-215 overexpression (29). However, previous studies have also demonstrated that miR-215 may be downregulated in epithelial ovarian (30), pancreatic (31), non-small cell lung (32), breast (33) and colon (34) cancer. In the study on pancreatic cancer, a low expression level of miR-215 was significantly associated with a large tumor size, an advanced TNM stage, a high extent of lymph node metastasis and vessel invasion, and lower overall survival time; multivariate regression analysis demonstrated that miR-215 underexpression was an independent unfavorable prognostic factor for patients (31).…”

Section: Discussionmentioning

confidence: 98%

“…In the study on pancreatic cancer, a low expression level of miR-215 was significantly associated with a large tumor size, an advanced TNM stage, a high extent of lymph node metastasis and vessel invasion, and lower overall survival time; multivariate regression analysis demonstrated that miR-215 underexpression was an independent unfavorable prognostic factor for patients (31). miR-215 expression was also reported to be associated with a higher tumor grade, human epidermal growth factor receptor 2 (HER2)-positivity, HER2-positive breast cancer subtype and lymph node metastasis in breast cancer (33). These studies have indicated that miR-215 may be a diagnostic and prognostic biomarker for a number of types of cancer.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

MicroRNA-215 acts as a tumor suppressor in breast cancer by targeting AKT serine/threonine kinase 1

et al. 2017

View full text Add to dashboard Cite

Abstract. There are accumulating reports that microRNAs are dysregulated in a number of human cancer types, and that they may function as tumor suppressors or oncogenes in tumorigenesis and tumor development. microRNA-215 (miR-215) has been identified as a tumor suppressor in epithelial ovarian, pancreatic, non-small cell lung and colon cancer, whereas it may act as an oncogene in gastric and cervical cancer. The role of miR-215 in breast cancer carcinogenesis and progression has yet to be elucidated. In the present study, the expression level of miR-215 was determined in breast cancer tissues and cell lines using the reverse transcription-quantitative polymerase chain reaction. The effects of miR-215 overexpression on proliferation and the invasive capacity of breast cancer cells were assessed using MTT and cell invasion assays. The results revealed that miR-215 was significantly downregulated in breast cancer tissues and cell lines. Restoration of miR-215 expression inhibited the proliferation and invasion of breast cancer cells. The underlying molecular mechanism for the suppression of proliferation and invasion by miR-215 was investigated. AKT serine/threonine kinase 1 (AKT1) was validated as a novel direct target of miR-215, and the effect of AKT1 small interfering RNA mimicked the effect of miR-215 overexpression in breast cancer cells. These results indicated that miR-215 acted as a tumor suppressor, and that its downregulation in tumor tissues may contribute to the carcinogenesis and progression of breast cancer, indicating that miR-215 may be a novel therapeutic target for the treatment of breast cancer.

show abstract

Section: Discussionmentioning

confidence: 98%

Section: Discussionmentioning

confidence: 99%

MicroRNA-215 acts as a tumor suppressor in breast cancer by targeting AKT serine/threonine kinase 1

et al. 2017

View full text Add to dashboard Cite

show abstract

“…MiR-215 was also identified as a putative anti-oncogenic miRNA through modulating a number of genes: up-regulated miR-215 causes a decrease in clonogenicity and mediates the repression of cell cycle and stemness genes downstream of CDX1 by targeting BMI1 in colon cancer (18,38), decreased cell migration and invasion in renal cell carcinoma (RCC) by targeting SIP1/ZEB2 and MMP3 (39); increased apoptosis by targeting XIAP in non-small cell lung cancer (40). However, up-regulation of miR-215 can also be observed in several studies such as gastric cancer, cervical cancer and hepatocellular carcinoma (41)(42)(43) (17). Prognostic significance of miR-215 expression has been revealed in many solid tumors, which suggests that it could serve as a potential role of prognostic biomarker and thereby create a more predictable future when refers to the clinical treatment of patients.…”

Section: Discussionmentioning

confidence: 99%

“…Previous studies showed that miR-215 could act as a tumor suppressor gene, and down-regulation of miR-215 was identified in several cancers, such as myeloma (14), nephroblastoma (15), esophageal adenocarcinoma (16), breast cancer (BC) (17) and colon cancer (18,19). However, the status of miR-215 expression and its prognostic value remain unclear in AML.…”

Section: Introductionmentioning

confidence: 99%

ReducedmiR-215expression predicts poor prognosis in patients with acute myeloid leukemia

Wang

Zhang

Yang

et al. 2016

Jpn. J. Clin. Oncol.

View full text Add to dashboard Cite

Objective: Abnormal expression of microRNA-215 has been identified in a variety of solid cancers. However, little is known about the expression pattern of microRNA-215 in acute myeloid leukemia. This study was to investigate the status of microRNA-215 expression and further analyze its clinical significance in acute myeloid leukemia. Methods: Real-time quantitative polymerase chain reaction assay was performed to evaluate the expression level of microRNA-215 in 113 patients with acute myeloid leukemia. Besides, the relationship between microRNA-215 levels and clinical and pathological factors was explored. Results: Compared with the healthy individuals, microRNA-215 expression in acute myeloid leukemia patients was significantly down-regulated (P = 0.001). MicroRNA-215 low-expressed patients had higher white blood cells than microRNA-215 high-expressed patients (P = 0.014). The incidence of FLT3/ITD mutation in the patients with low microRNA-215 expression was significantly higher than those with high microRNA-215 expression (P = 0.025). MicroRNA-215 low-expressed patients had significantly shorter overall survival than microRNA-215 high-expressed patients in both non-M3 acute myeloid leukemia patients and cytogenetically normal patients (P = 0.017 and P = 0.044, respectively). Meanwhile, multivariate analysis confirmed the adverse prognostic value of microRNA-215 expression in acute myeloid leukemia patients with non-M3 subtypes. Conclusions: Our study demonstrates that reduced microRNA-215 expression is a common event and is associated with poor clinical outcome in acute myeloid leukemia.

show abstract

“…miR-874 has been shown to inhibit cell proliferation and induce apoptosis by targeting CDK9 (13). miR-215 functions as a prognostic predictor for breast cancer with its high expression in cancer tissues and its association with other clinicopathological factors and the survival of patients (14). These data suggest an important role for miRNAs in the biology of BC.…”

Section: Introductionmentioning

confidence: 87%

microRNA-214 enhances the invasion ability of breast cancer cells by targeting p53

Wang

et al. 2015

International Journal of Molecular Medicine

View full text Add to dashboard Cite

Abstract. Breast cancer (BC) is the foremost cause of cancerrelated mortality in women worldwide. An increasing number of studies has confirmed that microRNAs (miRNAs or miRs) play an important role in the development and progression of BC. microRNA-214 (miR-214), a member of the miRNA family, has been demonstrated to function as both a tumor suppressor and oncogene in various types of human cancer. However, the biological function of miR-214 in BC remains unclear. The present study was designed to investigate the potential role of miR-214 in the development and progression of BC. Our results revealed that miR-214 expression was significantly increased in the BC tissues compared with the adjacent benign tissues, and that the upregulation of miR-214 was significantly associated with the invasion ability of the BC cells. Furthermore, p53, which has been reported to be downregulated in BC, was predicted to be the target gene of miR-214 using bioinformatics software programs. Moreover, luciferase reporter vectors were constructed and it was confirmed that p53 is a target of miR-214. Following the transfection of miR-214 into BC cells, we found that the overexpression of miR-214 markedly enhanced cell invasion through the downregulation of p53 expression. By contrast, the overexpression of p53 abrogated the effects of miR-214. In conclusion, this study demonstrates that miR-214 functions as an oncogene in BC, at least partly by promoting cell invasion through the downregulation of p53. Therefore, miR-214 may be a potential therapeutic target for the treatment of BC.

show abstract

Aberrant miR-215 expression is associated with clinical outcome in breast cancer patients

Cited by 30 publications

References 25 publications

MicroRNA-215 acts as a tumor suppressor in breast cancer by targeting AKT serine/threonine kinase 1

MicroRNA-215 acts as a tumor suppressor in breast cancer by targeting AKT serine/threonine kinase 1

ReducedmiR-215expression predicts poor prognosis in patients with acute myeloid leukemia

microRNA-214 enhances the invasion ability of breast cancer cells by targeting p53

Contact Info

Product

Resources

About